

Jana de Boniface

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2163764/publications.pdf>

Version: 2024-02-01

54
papers

1,607
citations

377584

21
h-index

355658

38
g-index

56
all docs

56
docs citations

56
times ranked

2405
citing authors

#	ARTICLE	IF	CITATIONS
1	ASO Visual Abstract: Retrospective Multicenter Analysis Comparing Conventional with Oncoplastic Breast-Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 1073-1075.	0.7	0
2	Retrospective, Multicenter Analysis Comparing Conventional with Oncoplastic Breast Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 1061-1070.	0.7	19
3	Eradication of Potential In-Transit Metastasis in Breast-Conserving Surgery—Reply. <i>JAMA Surgery</i> , 2022, 157, 174.	2.2	0
4	Abstract OT1-04-04: AXSANA - EUBREAST 3 (axillary surgery after neoadjuvant treatment): An international prospective multicenter cohort study of the EUBREAST study group to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary) Tj ETQq0 0 0 rgBT /Overclock 10 T6 50 617 Tc		
5	neoadjuvant chemotherapy (NCT04373655). <i>Cancer Research</i> , 2022, 82, OT1-04-04-OT1-04-04. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial. <i>Breast</i> , 2022, 63, 16-23.	0.9	14
6	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	0.9	22
7	False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 589-595.	1.1	14
8	Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. <i>British Journal of Surgery</i> , 2022, 109, 857-863.	0.1	22
9	AXSANA – AXillary Surgery After NeoAdjuvant Treatment: Eine prospektive, multizentrische Kohortenstudie der EUBREAST-Studiengruppe zur Bewertung verschiedener chirurgischer Verfahren des axillären Stagings bei initial nodal-positiven PatientInnen nach neoadjuvanter Chemotherapie. , 2022,...		0
10	Recurrence and survival after standard versus oncoplastic breast-conserving surgery for breast cancer. <i>BJS Open</i> , 2021, 5, .	0.7	13
11	Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study. <i>Cancers</i> , 2021, 13, 1565.	1.7	85
12	Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial. <i>British Journal of Surgery</i> , 2021, 108, 1105-1111.	0.1	7
13	Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status. <i>JAMA Surgery</i> , 2021, 156, 628.	2.2	122
14	Survival in breast cancer patients with a delayed DIEP flap breast reconstruction after adjustment for socioeconomic status and comorbidity. <i>Breast</i> , 2021, 59, 383-392.	0.9	3
15	Effect of radiotherapy on expanders and permanent implants in immediate breast reconstruction: long-term surgical and patient-reported outcomes in a large multicentre cohort. <i>British Journal of Surgery</i> , 2021, 108, 1474-1482.	0.1	5
16	Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial. <i>British Journal of Surgery</i> , 2021, 108, 302-307.	0.1	28
17	Targeted Removal of Axillary Lymph Nodes After Carbon Marking in Patients with Breast Cancer Treated with Primary Chemotherapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 1121-1127.	0.8	6
18	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. <i>BMJ Open</i> , 2021, 11, e045239.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 721-729.	1.1	12
20	Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 91-99.	0.9	8
21	Knowledge gaps in oncoplastic breast surgery. <i>Lancet Oncology</i> , The, 2020, 21, e375-e385.	5.1	34
22	Breast reconstruction patterns from a Swedish nation-wide survey. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1867-1873.	0.5	5
23	Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 977-984.	1.1	13
24	Immediate Breast Reconstruction. <i>Breast Care</i> , 2020, 15, 188-191.	0.8	1
25	The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 167-176.	1.1	9
26	Influence of socioeconomic status on immediate breast reconstruction rate, patient information and involvement in surgical decision-making. <i>BJS Open</i> , 2020, 4, 232-240.	0.7	8
27	Abstract OT3-01-01: Feasibility of carbon tattooing for targeted lymph node biopsy in breast cancer patients treated by primary systemic therapy (TATTOO trial). , 2020, , .		1
28	CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2020, 130, 1185-1198.	3.9	139
29	Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 795-805.	1.1	37
30	Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 469-475.	1.1	10
31	A gap analysis of opportunities and priorities for breast surgical research. <i>Lancet Oncology</i> , The, 2019, 20, e1.	5.1	1
32	Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction. <i>British Journal of Surgery</i> , 2018, 105, 1435-1445.	0.1	12
33	What Is the Best Management of cN0pN1(sn) Breast Cancer Patients. <i>Breast Care</i> , 2018, 13, 331-336.	0.8	13
34	Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 359-369.	1.1	53
35	Breast-conserving surgery followed by whole-breast irradiation offers survival benefits over mastectomy without irradiation. <i>British Journal of Surgery</i> , 2018, 105, 1607-1614.	0.1	44
36	Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 93-101.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 103-110.	1.1	29
38	Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study. <i>British Journal of Surgery</i> , 2017, 104, 238-247.	0.1	29
39	Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. <i>BMC Cancer</i> , 2017, 17, 379.	1.1	109
40	Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 227.	1.8	56
41	National study of the impact of patient information and involvement in decision-making on immediate breast reconstruction rates. <i>British Journal of Surgery</i> , 2016, 103, 1640-1648.	0.1	20
42	Impact of previous surgery on sentinel lymph node mapping: Hybrid SPECT/CT before and after a unilateral diagnostic breast excision. <i>Breast</i> , 2016, 30, 32-38.	0.9	4
43	Oestrogen receptors $\beta 1$ and $\beta 2$ have divergent roles in breast cancer survival and lymph node metastasis. <i>British Journal of Cancer</i> , 2014, 111, 918-926.	2.9	20
44	The oncological safety of nipple-sparing mastectomy – A Swedish matched cohort study. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1209-1215.	0.5	73
45	Radiotherapy in implant-based immediate breast reconstruction: risk factors, surgical outcomes, and patient-reported outcome measures in a large Swedish multicenter cohort. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 591-601.	1.1	73
46	Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes. <i>Journal of Translational Medicine</i> , 2013, 11, 290.	1.8	53
47	Causes of false-negative sentinel node biopsy in patients with breast cancer. <i>British Journal of Surgery</i> , 2013, 100, 775-783.	0.1	13
48	Prediction of Non-Sentinel Lymph Node Status in Breast Cancer Patients with Sentinel Lymph Node Metastases: Evaluation of the Tenon Score. <i>Breast Cancer: Basic and Clinical Research</i> , 2012, 6, BCBCR.S8642.	0.6	14
49	Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. <i>Oncoimmunology</i> , 2012, 1, 1305-1312.	2.1	61
50	Tumor-dependent downregulation of the $\beta 2$ -microglobulin chain in T cells is detectable in early breast cancer and correlates with immune cell function. <i>International Journal of Cancer</i> , 2012, 131, 129-139.	2.3	26
51	Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. <i>International Journal of Cancer</i> , 2012, 131, 1611-1620.	2.3	43
52	Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. <i>British Journal of Surgery</i> , 2012, 99, 226-231.	0.1	34
53	Breast Cancer Survival in Relation to the Metastatic Tumor Burden in Axillary Lymph Nodes. <i>Journal of Clinical Oncology</i> , 2010, 28, 2868-2873.	0.8	94
54	Axillary Recurrence Rate After Negative Sentinel Node Biopsy in Breast Cancer. <i>Annals of Surgery</i> , 2008, 247, 150-156.	2.1	81